Viking Therapeutics will launch a longship into phase 3 for the obesity drug VK2735 sooner than expected, with a clinical program expected to top $300 million. The biotech—which was launched into the ...
Pills that work similarly to currently available injectable medications represent the next wave of metabolic disorder drugs, and Viking Therapeutics is pushing its drug candidate to the forefront with ...
Brian Lian, President and CEO, reported that "the Viking team continued to focus on execution of our core clinical strategy," emphasizing advancement of both oral and subcutaneous VK2735 programs. "We ...
Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the 11 Best Short Squeeze Stocks to Buy Now. The company plans to accelerate the oral formulation of VK2735 following Phase 2 results and has also ...
Hosted on MSN
Viking Therapeutics, Inc. (VKTX) Nears Obesity Drug Breakthrough with Phase 3 VK2735 Trial
We recently compiled a list of 11 Best Future Stocks to Buy Now. Viking Therapeutics, Inc. stands third on our list. Viking Therapeutics, Inc. (NASDAQ:VKTX) is a clinical-stage biopharma company ...
VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone beta receptor (TRβ) that possesses selectivity for liver tissue, as well as the beta receptor ...
SAN DIEGO, March 26, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results